ArticleSubstance abuse treatment, prevention, and policy2026
Economic and epidemiological burden of medical complications of unregulated drug use among people who inject drugs in Québec.
Article in Substance abuse treatment, prevention, and policy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundOver the past decade, the prevalence of injection drug use and drug-related harms has increased significantly in Québec. Our study aims to characterize the economic and epidemiological burdens of medical complications of unregulated drug use, including injection-related infections (IRI), drug-related poisoning, and encephalopathy among people who inject drugs (PWID).
methodsWe utilized Québec administrative health data from April 2014 to March 2019 to describe the direct healthcare costs and the number of episodes of the medical complications of unregulated drug use during each fiscal year (FY). We computed outpatient, emergency department, inpatient, and medication costs and presented them in 2022 Canadian dollars.
resultsThe total direct healthcare cost of IRI, drug-related poisoning, and encephalopathy between FY 2014-2015 and FY 2018-2019 was $82,765,226, with costs increasing over time for all three complications. During the same period, the number of episodes increased from 1,300 to 5,595 for IRI, 695 to 1,030 for drug-related poisoning, and 85 to 350 for encephalopathy. Similarly, the number of unique patients who experienced medical complications increased from 860 to 3630 for IRI, 665 to 930 for drug-related poisoning, and 60 to 195 for encephalopathy. The costs and number of episodes were highest in Montréal, Montérégie, and Capitale-Nationale (Québec City) regions.
conclusionThe economic and clinical burden of medical complications of unregulated drug use among PWID in Québec is increasing. Public health interventions and dedication of resources are crucial to mitigating healthcare costs and improving health outcomes for people who inject drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.